Pascal M. W. Drake

TL;DR: Molecular farming in plants has already proven to be a successful way of producing a range of technical proteins and the first plant-derived recombinant pharmaceutical proteins are now approaching commercial approval, and many more are expected to follow.

TL;DR: How GM plants may impact on human health both directly – through applications targeted at nutrition and enhancement of recombinant medicine production – but also indirectly, through potential effects on the environment, is examined.

TL;DR: To answer the question of the potential immunogenicity of parenterally administered plant recombinant antibodies in animals, mice were immunised subcutaneously with a recombinant mouse monoclonal antibody produced in tobacco plants, together with alum as adjuvant andalyses showed undetectable levels of antibody directed against both the protein and the glycan part of the plant recombinic antibody.

TL;DR: It is demonstrated that the folding and assembly of IgG in transgenic tobacco plants is orchestrated by BiP (binding protein), an endoplasmic reticulum resident chaperone, which indicates that BiP, but not calreticulin, takes part in immunoglobulin folding andAssembly in transogenic plants.

TL;DR: The engineering of a human immunodeficiency virus-1 (HIV-1) p24-immunoglobulin A (IgA) antigen-antibody fusion molecule for therapeutic purposes and its enhancing effect on fused antigen expression in tobacco plants is described.